Trial Profile

A Phase 2 Clinical Trial of a Tau Morphomer (ACI-3024) for the Treatment of Alzheimers Disease (AD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACI 3024 (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use
Sponsors AC Immune

Most Recent Events

31 Mar 2020 New trial record
23 Mar 2020 According to an AC Immune media release, under the updated collaboration terms, AC Immune now is eligible for a new additional milestone payment of CHF 60 million within 60 days after dosing of the first patient in the first Phase 2 clinical trial of a Tau Morphomer in the United States or European Union

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com